BusinessAbeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten DiseaseBy Nasdaq OMXApr 20, 2018, 12:15 PM UTC
BusinessAbeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 DiseaseBy Nasdaq OMXMar 15, 2018, 12:45 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten DiseaseBy Nasdaq OMXFeb 12, 2018, 1:45 PM UTC
